HEALTHPOINT and Coria Align as DFB Branded Pharmaceuticals


FORT WORTH, Texas -- H. Paul Dorman, chairman and CEO of Fort Worth-based DFB Pharmaceuticals, Inc., has reorganized the company to place all branded DFB pharmaceutical businesses under DFB Branded Pharmaceuticals, with HEALTHPOINT(R), Ltd., veteran Michael E. Steadman at the helm.

DFB Branded Pharmaceuticals is one of three DFB business segments. The other two are DFB Pharmaceutical Services, represented by DPT Laboratories, Ltd. (San Antonio, Texas, and Lakewood, N.J.) and DFB Biotechnology, represented by Phyton Biotech, Inc. (Princeton, N.J., and Ahrensburg, Germany).

The realignment unites HEALTHPOINT Tissue Management; Coria Laboratories, Ltd.; HEALTHPOINT International; and HEALTHPOINT Surgical as the new DFB Branded Pharmaceuticals. With the change, the two formerly autonomous Tissue Management and Surgical divisions combine under one HEALTHPOINT umbrella.

"DFB and its operating companies have achieved astonishingly rapid yet sustainable growth in an increasingly complex environment," Dorman said. "With this new structure, we streamline our business, continue momentum, and create an even stronger launch pad for future expansion."

DFB Branded Pharmaceuticals has a workforce of approximately 400, with over half of the segment's employees in field sales roles. This team will market proprietary over-the-counter, prescription, and biopharmaceutical products for skin and soft tissue indications for HEALTHPOINT and Coria. The segment will also explore potential expansion into other niche markets domestically and internationally.

According to Dorman, DFB centralized functions like regulatory, medical, and clinical affairs will be leveraged and aligned to provide specialized support to both Coria and HEALTHPOINT. Research and development will be more closely associated with, and accountable for, the commercial product portfolios of each division.

All branded pharmaceutical businesses and managerial support functions will be located at the DFB Fort Worth headquarters campus.

Steadman, most recently senior vice president of DFB and president of the HEALTHPOINT Tissue Management division, will step up to lead DFB Branded Pharmaceuticals as group president and chief operating officer. In leadership positions for the commercial divisions are Rob Bancroft, general manager of HEALTHPOINT and Steve Clark, president of Coria. Outside the U.S., the segment's endeavors are led by Jay Nisbet, senior director of international.

DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide.

Source: DFB Pharmaceuticals, Inc.

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content